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The signalling pathway leading, for example, to actin
cytoskeletal reorganisation, secretion or superoxide
generation involves phospholipase D (PLD)-catalysed
hydrolysis of phosphatidylcholine to generate
phosphatidic acid, which appears to mediate the
messenger functions of this pathway [1–3].  Two PLD
genes (PLD1 and PLD2) with similar domain structures
have been cloned and progress has been made in
identifying the protein regulators of PLD1 activation, for
example Arf and Rho family members [4,5]. The activities
of both PLD isoforms are dependent on
phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) and
our sequence analysis suggested the presence of a
pleckstrin homology (PH) domain in PLD1, although its
absence has also been claimed [4]. Investigation of the
inositide dependence showed that a bis-phosphorylated
lipid with a vicinal pair of phosphates was required for
PLD1 activity. Furthermore, PLD1 bound specifically and
with high affinity to lipid surfaces containing PI(4,5)P2
independently of the substrate phosphatidylcholine,
suggesting a key role for the PH domain in PLD function.
Importantly, a glutathione-S-transferase (GST) fusion
protein comprising GST and the PH domain of PLD1
(GST–PLD1-PH) also bound specifically to supported
lipid monolayers containing PI(4,5)P2. Point mutations
within the PLD1 PH domain inhibited enzyme activity,
whereas deletion of the domain both inhibited enzyme
activity and disrupted normal PLD1 localisation. Thus,
the functional PH domain regulates PLD by mediating its
interaction with polyphosphoinositide-containing
membranes; this might also induce a conformational
change, thereby regulating catalytic activity.
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Results and discussion
Phosphatidylcholine hydrolysis catalysed in vitro by
PLD1b, the most commonly expressed PLD isoform,
fused to GST (GST–PLD1b) is dependent on the presen-
ceP of small G proteins and PI(4,5)P2 [4,5]. Table 1 shows
that, compared with phosphatidylserine, both natural and
synthetic PI(4,5)P2 and PI(3,4)P2 were effective activators
of PLD1b-catalysed phosphatidylcholine hydrolysis.
PI(3,4,5)P3, PI(3,5)P2, phosphatidylinositol 3-phosphate
(PI3P) and phosphatidylinositol stimulated PLD activity
only slightly. The same rank order of potency was
obtained when the small GTP-binding protein Cdc42 or
RhoA was substituted for Rac1 in the PLD assay (data not
shown). Thus, synthetic and saturated inositol lipids were
as effective in stimulating PLD as the natural (polyunsat-
urated) PI(4,5)P2. Neither inositol 1,4,5-trisphosphate
(Ins(1,4,5)P3), the headgroup of PI(4,5)P2, nor diacylglyc-
erol could support PLD activity [6]. Chemical removal of
the acyl chains from PI(4,5)P2 generated glycerophos-
phatidylinositol 4,5-bisphosphate, which could not
support PLD activity (data not shown).
The original report of the cloning of the PLD genes sug-
gested that they contain no known polyphosphoinositide-
binding domains [4]. Searches of the non-redundant
sequence database held at the National Center for Biotech-
nology Information using PSI-BLAST, however, revealed
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Table 1
Polyphosphoinositide dependence of PLD1b activity.
Activating phospholipid Mean PLD activity (range) (dpm)
Phosphatidylserine (n) 1,607 (180)
Phosphatidylinositol (s) 2,661 (258)
sPtdIns3P 5,501 (163)
sPtdIns(3,4)P2 17,842 (547)
sPtdIns(3,5)P2 5,135 (352)
sPtdIns(4,5)P2 16,762 (357)
sPtdIns(3,4,5)P3 7,971 (901)
nPtdIns(4,5)P2 19,571 (368)
Purified recombinant GST–PLD1 was assayed in the presence of
Rac1 with vesicles containing phosphatidylethanolamine,
phosphatidylcholine and the indicated natural (n) or synthetic (s)
phospholipid [5]. Data are presented as mean decays per min (dpm)
from duplicate experiments plus the range (indicated in parentheses).
Similar results were obtained in several experiments.
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significant sequence similarity between known PH
domains and a region of PLD1 and PLD2 located between
the PX and catalytic domains [7]. An alignment of the PH
domains of PLD1 and PLD2 with the PH domains of other
proteins, including pleckstrin, phospholipase Cδ and
Bruton’s tyrosine kinase (Btk), is presented in Figure 1.
Interestingly, amino acids assigned to the inositol-phos-
phate-binding site in the PH domain of Btk are conserved
in the PH domain of PLD1 and PLD2 (Lys228, Ser230 and
Arg253). Two recent theoretical studies using complemen-
tary methods have also suggested that PLD contains a PH
domain [8,9]. As PH domains have been suggested to bind
polyphosphoinositides specifically, and in view of the
results shown in Table 1, it was considered that PLD1
might bind polyphosphoinositides. 
Surface plasmon resonance (SPR) has been used to quan-
tify the interaction of bacterial toxins with gangliosides [10],
the binding of lipid vesicles to immobilised proteins [11]
and the interaction of phosphoinositide-dependent kinase 1
(PDK1) with supported lipid monolayers [12]. The interac-
tion of PLD with lipid monolayers comprising phos-
phatidylethanolamine, phosphatidylcholine and an
activating lipid such as PI(4,5)P2, was assessed by SPR.
Efficiently coated hydrophobic surfaces bound very little
bovine serum albumin and no free GST or GST–Janus-
kinase-2 in the presence or absence of polyphosphoinosi-
tides (data not shown). A GST fusion containing the PH
domain of the insulin receptor substrate 1 (GST–IRS1-
PH) bound specifically to lipid surfaces containing
natural or synthetic PI(4,5)P2, but interacted weakly with
surfaces containing phosphatidylserine or PI(3,4,5)P3
(data not shown), as in previous studies of PI(4,5)P2-
dependent vesicle binding to antibody-immobilised
GST–IRS1-PH [11]. Figure 2a shows that PLD1b inter-
acted with PI(4,5)P2 and PI(3,4)P2, both of which could
support enzyme activity. Conversely, phosphatidylser-
ine, phosphatidylinositol, PI(3,5)P2 and PI(3,4,5)P3 did
not support PLD activity and could not provide an effi-
cient binding site for PLD. Although PLD bound to sup-
ported lipid monolayers containing PI3P, this lipid
stimulated PLD activity only weakly (Table 1). Like
PLD1, other PH domains, including those from phos-
pholipase Cδ, diacylglycerol kinase-δ and β-adrenergic
receptor kinase-1, exhibit a similar degree of promiscuity
in their binding specificities by binding both PI(3,4)P2
and PI(4,5)P2 [13].
The binding of PLD1b to PI(3,4)P2 and PI3P raises the
possibility that PLD activity might be directly regulated
by phosphatidylinositol 3-OH kinase (PI3K) lipid prod-
ucts. However, the cellular level of PI(4,5)P2 exceeds
agonist-stimulated levels of PI(3,4,5)P3, PI(3,4)P2 or
PI3P. Furthermore, PLD activity has been shown to be
agonist responsive in the absence of measurable PI3K
activity [2]. It seems likely, therefore, that any role for
PI3K in the regulation of PLD activity is indirect. In this
regard, PI(3,4,5)P3 has been shown to regulate the GTP
status of Arf by interacting with the PH domain of the Arf
guanine-nucleotide exchange factor ARNO [14]. 
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Figure 1
Alignment of PLD and Btk PH domains.
Searches of protein sequences
(ftp://ncbi.nlm.nih.gov/blast/db/nr) used the
position-specific and iterative version of
BLAST (PSI-BLAST) with no filters and an
E-value inclusion threshold of E = 0.001.
Alignment of PLD sequences against
multiple alignments of known PH domains
used the web-based resource
(http://coot.embl-heidelberg.de/SMART/;
[16]). The alignments were coloured after
80% consensus (calculated using
http://bork.embl.heidelberg.de/cgi/consensus).
Human (H) PLD1 and PLD2 PH domain
sequences were compared with structure-
based alignment of PH domain sequences of
known high-resolution structure; sequence
databases are held at NCBI. The
carboxy-terminal sequence of the PI(3,4,5)P3-
binding protein [17] (amino acids 248–356)
showed a significantly similar sequence in
mouse PLD1b (amino acids 223–239) after
four iterations (E = 3 × 10–4). The alignment is
coloured after 80% consensus of the PH
domain alignment available from SMART,
β-strands (E) and α helices (H) are indicated
beneath the alignment. The PDB codes are
given following the alignment. Big (b) residues
E, F, I, K, L, M, Q, R, W, Y (amino-acid
single-letter notation) are shown red-on-grey;
hydrophobic (h) residues A, C, F, I, L, M, V,
W, Y and aliphatic (l) residues are shaded in
yellow; polar (p) residues D, E, H, K, N, Q, R,
S, T are in brown; and small (s) residues A, C,
S, T, D, N, V, G, P are in green. A tryptophan,
conserved in most PH domains, is indicated
by the filled box. Residues substituted in
patients with X-linked agammaglobulinaemia,
are indicated by the red triangle. Residues in
human PLD1 variants mutated in this study
are indicated by a blue triangle. Residues in
Btk that have been assigned to its
Ins(1,3,4,5)P4-binding site are underlined.
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The interaction of PLD1b with supported lipid monolayers
was not reduced in the absence of the phosphatidylcholine
(data not shown) and therefore appeared to be independent
of the active site. We determined that PLD had an appar-
ent affinity of 2 nM ± 1 nM for monolayers containing
PI(4,5)P2 in phosphatidylethanolamine. Analysis of these
data, using BIA evaluation 3.0 software, suggested that the
data fitted a simple 1 to 1 binding model (χ2 < 0.25). The
high affinity of PLD1 for PI(4,5)P2 is similar to the reported
affinity of 1.6 nM for PDK1 binding to PI(3,4,5)P3 [12]. A
GST fusion protein of the PLD1b PH domain (amino acids
218–330 inclusive; GST–PLD-PH) was expressed and puri-
fied from Escherichia coli. Figure 2b shows that this domain
bound to supported lipid monolayers containing PI(4,5)P2,
but interacted weakly with layers containing PI3P and
PIP3, indicating that the isolated PH domain and complete
PLD1b have similar polyphosphoinositide-binding speci-
ficities. Recombinant GST did not interact with supported
lipid monolayers in the presence or absence of polyphos-
phoinositides (data not shown). The interaction of PI3P
with PLD1b, but not with the isolated PH domain, corre-
sponds to the inability of this lipid to support catalytic activ-
ity, suggesting that its binding site is elsewhere in PLD.
Mutations of residues in the PH domain of Btk have been
characterised in patients with X-linked agammaglobuli-
naemia (XLA). Of these, Phe25 to Ser or Arg28 to His in β
strand 2, have been shown to reduce binding of inositol
phosphate [15]. The corresponding residues in PLD1 and
PLD2 are Trp250 and Arg253. Additionally, amino acids
substituted in β strand 1 of Btk in XLA patients (Lys12 to
Arg and Ser14 to Phe) are also conserved in PLD. In
human PLD1 these residues correspond to Lys228 and
Ser230. Thus, mutations analogous to those in the Btk PH
domain were introduced into the PH domain of PLD1b.
Lys228 was mutated to Arg, Ser230 to Phe, Phe250 to Ser
and Arg253 to Cys. Wild-type and mutated PLD1b genes
were expressed as green fluorescent protein (GFP) fusions
in COS-1 cells that have low endogenous PLD activity
(Figure 2c). The transfected PLD activity was determined
in cell lysates, using HL60 cell cytosol as a source of nec-
essary protein activators. Mutation of the conserved
residues within the PH domain of PLD1 dramatically
reduced basal and stimulated enzyme activity (Figure 2c).
Comparable results were obtained with PLD mutants
tagged with haemagglutinin (HA) at the amino terminus
(data not shown). Mutation of a potentially non-critical
residue within the PH domain did not affect PLD activity
(data not shown). Finally, deletion of the PH domain from
PLD1b (GFP–∆PH-PLD1b) generated an inactive PLD. 
The localisation of wild-type HA-tagged PLD1b
(HA–WT-PLD1b) and the GFP-tagged PLD1b with a
deleted PH domain (GFP–∆PH-PLD1b) was examined
following transient transfection. The two PLD1b con-
structs did not co-localise in IIC9 fibroblasts (Figure 2d).
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Figure 2
PLD1 requires a functional PH domain for
binding to supported lipid monolayers,
enzyme activity and localisation.
(a) GST–human PLD1b was specifically
bound to supported lipid monolayer surfaces
containing natural PI(4,5)P2.
Phosphatidylserine (PtdSer) or PI(4,5)P2
(Lipid Products) or synthetic C16-
polyphosphoinositides (phosphatidylinositol
(PI), PI3P, PI(3,4)P2, PI(3,5)P2, PI(4,5)P2 and
PI(3,4,5)P3 (Echelon Lipids) were presented
to PLD in supported lipid monolayers of
phosphatidylethanolamine (PtdEtn) and
phosphatidylcholine (PtdCho), and similar
results were obtained in two other
experiments. (b) The PH domain of PLD1
bound specifically to PI(4,5)P2-containing
supported lipid monolayers. Purified
recombinant GST–PH domain of PLD1b was
injected across supported lipid monolayers
containing phosphatidylethanolamine and
phosphatidylcholine (red) plus the indicated
polyphosphoinositide (PI(4,5)P2, blue;
PI(3,4,5)P3, pink; PI3P, green). GST alone did
not interact with these layers. Similar results
were obtained in two other experiments.
(c) Mutation of critical residues in the PH
domain of PLD inhibited enzyme activity. The
activity of mutant PLD constructs transfected
and expressed in COS-1 cells was quantified.
Data represent means from duplicate
determinations plus range, and similar results
were obtained in at least three other
experiments. (d) Localisation of HA–WT-
hPLD1b and GFP–∆PH-hPLD1b in IIC9 cells.
HA–WT-hPLD1b was detected with Texas
Red-conjugated secondary antibody. The
localisation of GFP–∆PH-PLD1b (green) and
HA–WT-hPLD1b (red) was assessed by
confocal microscopy.
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Wild-type PLD1b localised to an endosomal or lysosmal
compartment, consistent with our previous observations
in COS-1 and RBL-2H3 cells [3]. In contrast,
GFP–∆PH-PLD1b assumed a punctate distribution
throughout the cell; however, it was not possible to
define its location. Mutation of single amino acids in the
PH domain of PLD1 (as above) did not affect localisation
(data not shown). These observations demonstrate a crit-
ical role for the PH domain in regulating the subcellular
localisation of PLD1b.
Our results show that human PLD1 contains a functional
PH domain. The polyphosphoinositide dependence of
PLD1b activity can be ascribed to the ability of the enzyme
to physically interact with lipids via the PH domain. Point
mutations within the PH domain inhibited PLD activity,
while deletion of the PH domain both inhibited enzyme
activity and distorted the normal subcellular localisation of
PLD1b, emphasising the essential role of the PH domain in
the control of both enzyme activity and subcellular localisa-
tion. It has been reported previously that PH domains
promote both membrane interaction and increased enzy-
matic activity of signalling proteins [14]. Finally, our results
suggest that the interaction of PLD with PI(4,5)P2-bearing
membranes may be a key event leading to the formation of
a multicomponent complex of lipids and regulatory pro-
teins, resulting in phosphatidylcholine hydrolysis.
Materials and methods
Expression and purification of GST–PLD1b
GST–PLD1b was expressed in insect cells, purified and assayed as
previously described [5]. GST–IRS1-(PH) (a generous gift of G. Panay-
otou, Ludwig Institute, London), free GST and GST–PLD1b-PH were
expressed in E. coli and purified by glutathione–Sepharose affinity
chromatography and gel filtration. GST–Janus-kinase-2 was from Santa
Cruz Biologicals.
Surface plasmon resonance analysis of the binding of PLD1b
to supported lipid monolayers
Surface plasmon resonance was performed using a Biacore 2000 and
hydrophobic HPA chips (Biacore UK). Supported lipid monolayers
were formed following injection of 2% octylglucoside into 300 µM
extruded unilamellar vesicles (phosphatidylethanolamine 85mol%;
phosphatidylcholine 5mol%; PI(4,5)P2 or acidic lipid as indicated
10mol%) across the HPA surface at 3 µl/min. Surfaces were subjected
to a high flow rate, several injections of 100 mM HCl and 10 µg BSA
[10]. Specificity experiments utilised GST–PLD1b (50 nM) or
GST–PLD1-PH (100 nM) at a flow rate of 5 µl/min, while the affinity of
PLD1b for the surface was determined at 1–25 nM at flow rates of
10, 20 and 30 µl/min.
Expression of GFP–PLD1b mutants in COS-1 cells 
Human PLD1b (hPLD1b) was subcloned into the GFP vector eGFP to
produce the amino-terminal fusion protein GFP–hPLD1b [3]. The PLD
point mutants (K228R, S230F, W250S, R253C) were obtained by
PCR site-directed mutagenesis and subcloned back into eGFP con-
taining wild-type hPLD1b. GFP–PLD1b-PH was generated by
Expand High Fidelity PCR system (Roche Diagnostics). COS-1 cells
(1 × 106) were transiently transfected with 5 µg DNA constructs in the
presence of polyethylenimine, lysed after 24 h, and PLD activity deter-
mined in the presence and absence of HL60 cytosol [5]. 
Expression of HA–WT-PLD1 and GFP–∆PH-PLD1b in IIC9
fibroblasts
IIC9 fibroblasts were transfected with 200 ng HA–WT-PLD1 DNA and
GFP–∆PH-PLD1b in the presence of 1.5 µl FugeneTM. After 24 h cells
were fixed, permeabilised and incubated with primary antibody (12CA5,
mouse anti-HA) and goat anti-mouse IgG labelled with Texas Red. Fluo-
rescence was detected using a deconvoluting confocal microscope. 
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